A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)

Exclusion Criteria

• •Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of study participation
• •Patient has a history of mild migraine attacks or migraines that resolve in less than 2 hours
• •Patient has basilar or hemiplegic migraine headaches
• •Patient has \>15 headache-days per month OR has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening
• •Patient has uncontrolled high blood pressure, uncontrolled diabetes, human immunodeficiency virus (HIV), any cancer, or any other significant disease
• •Patient has a history cardiovascular problems or stroke
• •Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to rizatriptan
• •Patient has demonstrated hypersensitivity to or experienced a serious adverse event in response to 3 or more classes of drugs (over-the-counter and prescription)
• •Patient did not experience satisfactory relief from migraine pain to prior treatment with 2 or more adequate courses of 5-hydroxytryptamine 1 (5HT1) agonists
• •Patient has a recent history (within the past year) or current evidence of drug or alcohol abuse or is a "recreational user" of illicit drugs
• •Patient is currently taking monoamine oxidase inhibitors, methysergide, or propranolol, and is unable to tolerate withdrawal of these medications for the intervals required
• •Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of screening
• •Patient is legally or mentally incapacitated